$CTMX
CytomX Therapeutics Inc

2022 Q1 Form 10-Q Financial Statement

#000095017022007806 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $17.14M $15.97M
YoY Change 7.29% -67.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.54M $9.230M
YoY Change 14.23% -3.55%
% of Gross Profit
Research & Development $30.56M $22.37M
YoY Change 36.6% -47.74%
% of Gross Profit
Depreciation & Amortization $602.0K $600.0K
YoY Change 0.33% 0.0%
% of Gross Profit
Operating Expenses $41.10M $31.60M
YoY Change 30.08% -39.68%
Operating Profit -$23.97M -$15.63M
YoY Change 53.36%
Interest Expense $68.00K $70.00K
YoY Change -2.86% -93.52%
% of Operating Profit
Other Income/Expense, Net $13.00K $5.000K
YoY Change 160.0% -50.0%
Pretax Income -$23.89M -$15.55M
YoY Change 53.6% 809.36%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.89M -$15.55M
YoY Change 53.56% -227.44%
Net Earnings / Revenue -139.38% -97.39%
Basic Earnings Per Share
Diluted Earnings Per Share -$365.2K -$255.0K
COMMON SHARES
Basic Shares Outstanding 65.39M 60.97M
Diluted Shares Outstanding 65.39M 60.97M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $262.5M $393.8M
YoY Change -33.33% 58.85%
Cash & Equivalents $163.5M $329.7M
Short-Term Investments $99.04M $64.10M
Other Short-Term Assets $4.898M $5.500M
YoY Change -10.95% -39.56%
Inventory
Prepaid Expenses
Receivables $1.016M $800.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $268.4M $400.0M
YoY Change -32.89% -0.02%
LONG-TERM ASSETS
Property, Plant & Equipment $6.093M $28.90M
YoY Change -78.92% -9.97%
Goodwill $949.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $902.0K $3.200M
YoY Change -71.81% 132.05%
Total Long-Term Assets $28.38M $34.20M
YoY Change -17.01% -6.46%
TOTAL ASSETS
Total Short-Term Assets $268.4M $400.0M
Total Long-Term Assets $28.38M $34.20M
Total Assets $296.8M $434.2M
YoY Change -31.64% -0.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.721M $2.600M
YoY Change -33.81% -31.25%
Accrued Expenses $31.03M $18.83M
YoY Change 64.79% -33.58%
Deferred Revenue $70.01M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $102.8M $98.00M
YoY Change 4.86% -7.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $125.9M $190.1M
YoY Change -33.79% -27.14%
Total Long-Term Liabilities $125.9M $190.1M
YoY Change -33.79% -27.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $102.8M $98.00M
Total Long-Term Liabilities $125.9M $190.1M
Total Liabilities $228.6M $288.1M
YoY Change -20.65% -21.47%
SHAREHOLDERS EQUITY
Retained Earnings -$557.6M -$465.7M
YoY Change 19.74%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.19M $146.0M
YoY Change
Total Liabilities & Shareholders Equity $296.8M $434.2M
YoY Change -31.63% -0.58%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$23.89M -$15.55M
YoY Change 53.56% -227.44%
Depreciation, Depletion And Amortization $602.0K $600.0K
YoY Change 0.33% 0.0%
Cash From Operating Activities -$41.31M -$29.94M
YoY Change 37.99% -39.8%
INVESTING ACTIVITIES
Capital Expenditures $736.0K $982.0K
YoY Change -25.05% -6.39%
Acquisitions
YoY Change
Other Investing Activities $0.00 $60.00M
YoY Change -100.0% 1614.29%
Cash From Investing Activities -$736.0K $59.01M
YoY Change -101.25% 2317.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $107.7M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.000K 108.7M
YoY Change -99.99% 4941.03%
NET CHANGE
Cash From Operating Activities -41.31M -29.94M
Cash From Investing Activities -736.0K 59.01M
Cash From Financing Activities 7.000K 108.7M
Net Change In Cash -42.04M 137.8M
YoY Change -130.51% -405.29%
FREE CASH FLOW
Cash From Operating Activities -$41.31M -$29.94M
Capital Expenditures $736.0K $982.0K
Free Cash Flow -$42.05M -$30.92M
YoY Change 35.98% -39.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001501989
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
515-3185
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CTMX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99696000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1016000
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65398355
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163488000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99042000
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37587
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022Q1 dei City Area Code
CityAreaCode
650
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
790000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4898000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4285000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
268444000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
310301000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6093000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5960000
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
984000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1021000
CY2022Q1 us-gaap Goodwill
Goodwill
949000
CY2021Q4 us-gaap Goodwill
Goodwill
949000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65398355
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
626721000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65398355
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65392758
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65392758
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10543000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9227000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
41102000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18536000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19362000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
902000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
901000
CY2022Q1 us-gaap Assets
Assets
296825000
CY2021Q4 us-gaap Assets
Assets
339411000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1721000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2818000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31032000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34236000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
70013000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
69262000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
102766000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
106316000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
108788000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
125660000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17077000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18056000
CY2022Q1 us-gaap Liabilities
Liabilities
228631000
CY2021Q4 us-gaap Liabilities
Liabilities
250032000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
623344000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-919000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-242000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-557609000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-533724000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
68194000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89379000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
296825000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339411000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17136000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15971000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30559000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22371000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-15554000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1023000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
146022000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-23885000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
31598000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23966000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15627000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
68000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
68000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23885000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-677000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24562000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15550000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.37
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.26
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65393691
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60968111
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89379000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3370000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-677000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23885000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
68194000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107712000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
36000
CY2022Q1 ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
565000
CY2021Q1 ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
638000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
17000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-141000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3370000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3034000
CY2022Q1 ctmx Noncash Lease Expense
NoncashLeaseExpense
-826000
CY2021Q1 ctmx Noncash Lease Expense
NoncashLeaseExpense
-759000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
232000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
613000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1640000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
74000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1060000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-292000
CY2022Q1 ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-4182000
CY2021Q1 ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-5096000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-16121000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
15214000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41313000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29940000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
736000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
982000
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
59994000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-736000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59012000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107712000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1023000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108735000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-42042000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
137807000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
164405000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
330583000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Description of the Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163488000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
329666000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
164405000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
330583000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2022Q1 ctmx Cash Cash Equivalents And Short Term Investments Amortized Cost Basis
CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis
226609000
CY2022Q1 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
-919000
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
225690000
CY2021Q4 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
266591000
CY2021Q4 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
-242000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
266349000
CY2022Q1 ctmx Debt Securities Available For Sale Maturity Period
DebtSecuritiesAvailableForSaleMaturityPeriod
P12M
CY2022Q1 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
18307000
CY2021Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
18861000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5824000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9576000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2228000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1468000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3730000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3618000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
943000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
713000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31032000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34236000
CY2022Q1 us-gaap Revenues
Revenues
17136000
CY2021Q1 us-gaap Revenues
Revenues
15971000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
194922000
CY2022Q1 ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
16121000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
178801000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
178800000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12192216
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.42
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2556118
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.09
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5597
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.36
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
432428
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.79
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14310309
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.46
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3370000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3034000
CY2020Q1 ctmx Loss Contingency Answer Affirmative Defenses And Counterclaims Filing Date
LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate
2020-05-26
CY2020Q1 ctmx Loss Contingency Answer And Counterclaims By Plaintiff Filing Date
LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate
2020-06-05

Files In Submission

Name View Source Status
0000950170-22-007806-index-headers.html Edgar Link pending
0000950170-22-007806-index.html Edgar Link pending
0000950170-22-007806.txt Edgar Link pending
0000950170-22-007806-xbrl.zip Edgar Link pending
ctmx-20220331.htm Edgar Link pending
ctmx-20220331.xsd Edgar Link pending
ctmx-20220331_cal.xml Edgar Link unprocessable
ctmx-20220331_def.xml Edgar Link unprocessable
ctmx-20220331_htm.xml Edgar Link completed
ctmx-20220331_lab.xml Edgar Link unprocessable
ctmx-20220331_pre.xml Edgar Link unprocessable
ctmx-ex31_1.htm Edgar Link pending
ctmx-ex31_2.htm Edgar Link pending
ctmx-ex32_1.htm Edgar Link pending
ctmx-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending